PDT Partners LLC Decreases Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

PDT Partners LLC cut its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 50.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,712 shares of the company's stock after selling 39,942 shares during the quarter. PDT Partners LLC owned 0.07% of Harmony Biosciences worth $1,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Barclays PLC increased its position in Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company's stock valued at $3,074,000 after purchasing an additional 40,416 shares during the period. Franklin Resources Inc. raised its holdings in Harmony Biosciences by 6.1% in the third quarter. Franklin Resources Inc. now owns 29,773 shares of the company's stock worth $1,191,000 after purchasing an additional 1,720 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Harmony Biosciences by 68.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after purchasing an additional 93,622 shares in the last quarter. GAMMA Investing LLC increased its position in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after buying an additional 436 shares in the last quarter. Finally, CWA Asset Management Group LLC raised its stake in Harmony Biosciences by 27.0% during the fourth quarter. CWA Asset Management Group LLC now owns 18,279 shares of the company's stock valued at $629,000 after buying an additional 3,883 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded up $1.79 during trading hours on Tuesday, reaching $31.75. 616,623 shares of the stock traded hands, compared to its average volume of 576,197. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 15.09, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average price of $31.34 and a 200 day moving average price of $34.04.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. During the same period last year, the firm earned $0.67 earnings per share. The company's quarterly revenue was up 19.5% on a year-over-year basis. On average, equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HRMY. UBS Group lowered their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target on the stock. Mizuho boosted their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences has an average rating of "Buy" and an average price target of $52.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.